The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA just reversed the 2023 peptide ban. 14 peptides, including BPC 157, TB 500, GHK Cu, Epitalon, MOTS c, Semax, and MK 677, are returning to legal compounding under physician prescription. The door is open Is BPC 157 Banned? Oral vs. Injectable Forms Explained RFK Jr. and the Perils of Peptides Washington Monthly